Overview
- Gilead said it will acquire Ouro Medicines for $1.675 billion in cash upfront, with up to $500 million more tied to milestones.
- The deal centers on OM336, a BCMA–CD3 bispecific antibody that links T cells to plasma cells to remove them in autoimmune disease.
- Gilead disclosed it is finalizing a collaboration in which Galapagos would receive most Ouro assets and staff in exchange for co-funding about half the transaction and earning up to roughly 23% in royalties while Gilead keeps most commercial rights.
- Keymed Biosciences, which licensed OM336 to Ouro and owns about 15% of Ouro, expects about $250 million upfront and up to $70 million in milestones at closing.
- OM336, also called gamgertamig, is in trials for uncommon conditions such as autoimmune cytopenias, bullous diseases, idiopathic inflammatory myopathy, and Sjögren’s syndrome, reflecting a broader push to test T cell engagers as repeat-dose alternatives to cell therapies.